Preventive Care

AI Fairness: Data Governance to De-Risk Your Investment

Listen to this article · 6 min listen

If you think you can fix algorithmic fairness in healthcare AI with post-hoc model adjustments, you’re already starting from the wrong place. The entire effort has to begin with data governance. For any health plan looking at a new AI tool, the first question must be about the training data: whose clinical reality is actually in this dataset, and who’s been left out? You have to get an answer to that before you even start looking at model metrics.

Training Data Source and Clinical Claims Regulation

The origin of the training data directly determines if an AI model will work equitably across different kinds of people. Tempus AI, for instance, uses integrated clinical data sets for its cancer-focused tools, and the FDA’s 510(k) Pathway records draw a clear line around what kind of clinical claims can be made for these AI/ML medical devices. That regulatory process forces a company to prove its product is substantially equivalent to a device already on the market, which keeps the claims tied to what’s accepted in clinical practice.

Real-World Evidence Accumulation

Once a model is deployed, you start collecting data through Real-World Evidence (RWE) programs. This RWE, which comes from EHRs, patient registries, and insurance claims, is what supplements the original trial data and gives you a real picture of how the model is working in messy, heterogeneous settings. This constant flow of new data is what you use for ongoing model refinement, and it’s your best tool for spotting performance gaps that show up between different demographic groups. FDA framework for Real-World Evidence

Algorithmic Fairness and Data Governance

At its core, algorithmic fairness is a data governance problem. When a model consistently misses a certain diagnosis for a specific group of people, the root of that failure is almost always in the original data collection and curation. Julia Adler-Milstein’s research gets right to this point, questioning whether the data governance strategies in our health systems actually manage to include and represent everyone they’re supposed to serve (especially people who’ve been historically left out of clinical datasets).

Population Representation in Training Data

Biased training data is a recipe for algorithmic drift and it makes existing health inequities worse. If you train a model mostly on data from one demographic group, its accuracy will almost certainly fall off a cliff when you apply it to people with different clinical presentations or social determinants of health. What does strong data governance look like in practice? It means having explicit strategies to find, collect, and incorporate data from minority groups and other vulnerable populations to ensure the training set actually reflects the real world.

Failure Set Analysis: Evidence Gaps and Outcomes

The implosion of companies like Theranos and Olive AI wasn’t just bad luck. It’s a clear lesson on what happens without transparent evidence and rock-solid validation. Both companies got hit with intense scrutiny over their marketing claims and the (lack of) data backing up their tech. Their stories are cautionary tales for anyone evaluating AI health products today.

Peer-Reviewed Clinical Validation Deficiencies

Peer-reviewed clinical validation is a basic indicator of trust. It’s the independent verification that a model is safe, effective, and fair. When that validation is missing or flimsy, you’re taking on a huge amount of risk. Theranos, for example, couldn’t produce the rigorous, independent studies needed to back up its diagnostic claims. Olive AI ran into a similar wall when it struggled to show a consistent, positive ROI or clinical benefit that could be replicated across different hospital systems. RAND report on AI in healthcare adoption challenges These examples show a direct line between a lack of transparent, published outcomes and a product that is risky and untrustworthy.

Vendor Due Diligence: Governance Questions for Health Plans

If you’re a quality officer at a health plan auditing how an AI model performs across your member populations, you have to make data governance your top priority. The real work on fairness starts by digging into the vendor’s data acquisition strategy and figuring out what it means for population representation.

Key Governance Questions

  • Training Data Demographics: What’s the demographic breakdown of your training data? I need to see age, race, ethnicity, socioeconomic status, and geographic location.
  • Data Collection Bias Mitigation: How exactly do you find and correct for biases during data collection and annotation? Show me the process.
  • Data Sharing Agreements: What are the terms of your data sharing agreements? How are you ensuring patient privacy and security (are you HIPAA, HITRUST, and SOC 2 compliant)?
  • Real-World Performance Monitoring: What’s your process for continuously monitoring the model’s performance in the field, specifically looking at different population segments?
  • Adverse Event Reporting: When bias or a disparate impact is found after deployment, what is the mechanism for reporting it and how do you fix it? Commonwealth Fund research on equitable AI in health Fairness in AI health tools is an intrinsic property that comes directly from conscientious data governance. It isn’t a feature you can add on later. Health plans have to scrutinize the data foundation of any AI vendor to make sure the tool will deliver equitable and reliable outcomes for all their members.

Frequently Asked Questions

What is the primary factor to consider when evaluating AI tools for equitable performance across diverse populations?

The foundational question for evaluating AI tools centers on the training data: whose clinical realities are represented, and whose are systematically excluded. This inquiry precedes any assessment of model metrics or performance outcomes, as the provenance of training data directly impacts an AI model’s generalizability and equitable performance.

How does the article suggest health plans can ensure population representation in AI training data?

Health plans should prioritize robust data governance to ensure training data reflects the diversity of the intended user population. This includes explicit strategies for collecting and incorporating data from minority groups and other vulnerable populations. Algorithmic fairness is fundamentally a data governance challenge, originating in data collection and curation processes.

What role does Real-World Evidence (RWE) play in ensuring algorithmic fairness?

RWE, derived from electronic health records, registries, and claims data, supplements pivotal trial data and provides insights into model performance in heterogeneous real-world settings. This continuous data influx informs ongoing model refinement and helps identify potential performance disparities across demographic groups. It is crucial for monitoring model performance across different population segments.

Why is peer-reviewed clinical validation important for AI health products?

Peer-reviewed clinical validation represents a crucial trust indicator, providing independent verification of a model’s safety, efficacy, and fairness. The absence or inadequacy of such validation creates substantial risk, as seen in cases like Theranos. A lack of transparent, published outcomes evidence directly correlates with increased risk and diminished trustworthiness.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Trustworthy Health AI is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.